KDR and gastric cancer: Thus, targeting tumor angiogenesis is considered an important antitumor therapy.[9] Apatinib, a small molecule tyrosine kinase inhibitor with a high selectivity for vascular Endothelial growth factor receptor 2 (VEGFR2), exerts promising antitumor effect in various tumors.[10] In a third-phase clinical trial, apatinib has been proven to be a safe and effective drug in patients with advanced gastric cancer.[11] On that basis, apatinib was granted approval for the treatment of advanced gastric cancer by the China Food and Drug Administration (CFDA) in 2014.